by H.S. Ayoub
BioHealth Investor.com
On Tuesday Thermogenesis Corp (KOOL) announced that it had submitted the necessary paperwork answering certain questions the FDA had regarding its pre-market approval application for the CryoSeal Fibrin Sealant System.
The company had originally filed the application in early 2006.
CryoSeal is an automated device that could be used to produce fibrin sealants from a patient’s own blood during surgery. If approved, the CryoSeal system will add a substantial revenue stream in addition to the company’s stem cell collection and processing units.
Thermogenesis is expected to announce second quarter financial results this coming Friday, February 9th. First quarter results were very positive, and with the company’s continued distribution deal with GE Healthcare (GE) this Friday could prove to be a great day for investors.
Thermogenesis was featured by BioHealth Investor back in October, and was in fact BHI’s first stock pick.
http://www.biohealthinvestor.com/
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
